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S St tu ud dy y D De es si ig gn n:: This is a multicenter, open-label prospective, non interventional study.
P Pu ur rp po os se e:: We wanted to evaluate the impact of fentanyl matrix on the pain and function of patients with spinal disorder-
related chronic, non-malignant pain. 
O Ov ve er rv vi ie ew w o of f L Li it te er ra at tu ur re e:: Patients with severe non-malignant chronic low back pain may require opioid analgesics for effec-
tive pain management. 
M Me et th ho od ds s:: A total of 1,576 patients with severe pain (numeric rating scale = 7) were evaluated for their pain intensity at the
initial visit and at weeks 4 and 8 (Visits 1, 2, and 3, respectively). Disturbances in sleep, daily living and social activities, the
Oswestry Disability Index (ODI), the researchers’and patients’global assessment and the patients’treatment preference
were also assessed. 
R Re es su ul lt ts s:: The pain intensity score significantly decreased from 8.1 at Visit 1 to 5.4 and 4.4 at Visits 2 and 3, respectively.
Sleep disturbance also significantly decreased and the extent of disturbance of daily and social activities was also signifi-
cantly improved. The ODI significantly decreased from 61.9% to 45.8% and 38.2% at Visits 1, 2, and 3, respectively. Adverse
events were reported by 197 (12.5%) patients and severe adverse events were reported by 12 (0.76%) patients. Overall, 76.3%
of the patients and 78.4% of the investigators rated the test drug as effective. 
C Co on nc cl lu us si io on ns s:: The fentanyl matrix is believed to be effective for the treatment of pain, sleep disturbance and the impact upon
daily and social activities, yet physicians should pay attention to the risks of abuse and the adverse events. 
Key W Words: Chronic pain, Spine, Transdermal fentanyl, Functional improvement Introduction 
Non-opiates and non-steroidal anti-inflammatory drugs
(NSAIDs) remain the standard medical treatments for non-
malignant low back pain due to their effectiveness for pain
relief [1]. Acetaminophen therapy, although effective for
the treatment of mild or moderate pain, is limited by the risk
of hepatotoxicity when administered over extended periods
or at doses over 4 g/day, and there is an increased bleeding
tendency in patients taking warfarin combined with aceta-
minophen. NSAIDs are frequently used, but they are associ-
ated with ceiling effects and serious gastrointestinal bleed-
ing. 
Patients with more severe non-malignant chronic low
back pain may require opioids for effective pain manage-
ment. Opioids are known to participate in the pathway
between the internal analgesic system and the macula nucle-
ito spinal cord [2,3]. There have been several empirical
observations and controlled trials demonstrating that opi-
oids can provide significant relief for patients with non-
malignant chronic pain, with the resultant restoration of
daily activities and this is accompanied by a low risk of
serious adverse effects [4-8]. Transdermal fentanyl (TDF)
matrix, which provides systemic delivery of fentanyl at a
constant rate for 72 hours [9], has been shown to be effec-
tive for controlling pain in patients with chronic back pain
[8-10]. The potential advantages of TDF include the conve-
nience, continuous drug delivery and improved compliance
[11]. This open-label trial was undertaken to evaluate the
utility and safety of TDF for the treatment of chronic spinal
disorder-related pain under conditions that approximate
everyday medical practice. 
The primary objective of this study was to determine the
impact of TDF on improving pain and function in patients
with spinal disorder-related pain. The secondary objectives
included improvement on the Korean version of the
Oswestry Disability Index (K-ODI), sleep, everyday living,
and social activities. 
Materials and Methods
This was an open-label prospective, non interventional,
electronic web-based study conducted between May and
December 2008 at 63 orthopedic and neurosurgery-based
clinics in Korea. The study was designed to determine the
utility and side effects of the TDF patch (Durogesic
�
DTRANS, Janssen Korea, Seoul, Korea) for patients with
spinal disorder-related chronic pain that was not adequately
controlled by conventional conservative treatment.  
The Institutional Review Boards at each hospital
approved the study, and the study was carried out in accor-
dance with the Declaration of Helsinki and the principles of
good clinical practice. All the eligible patients provided
written informed consent before entering the study. 
1. Patient selection 
The patients who were aged at least 20 years with spinal
disorder-related chronic pain of more than 3 months dura-
tion, which remained severe (numeric rating scale [NRS] =
7) despite medication, were included in this study.  Patients
were excluded from the study if they had received fentanyl
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Table 1. Patient characteristics of total and full data analysis
set (FAS) patients
Characteristics
Total (n = 1,576) FAS (n = 1,252)
Mean Std Mean Std
Age (yr) 62.8 12.9 063.29 12.66
Height (cm) 161.8 09.5 160.96 09.85
Weight (kg) 60.3 10.6 060.38 10.77
Gender
Male 606 (38.5) 505 (40.34)
Female 970 (61.5) 747 (59.66)
Values are presented as number (%).
FAS: Full data analysis set, Std: Standard deviation.
Table 2. Diagnosis of total and FAS patients 
Diagnosis Total FAS 
Degenerative spine disease 970 (61.6) 765 (61.6) 
Spinal stenosis 497 (31.5) 388 (31.0) 
Herniated intervertebral disc 242 (15.4) 190 (25.2)
Degenerative disc disease 126 (8.0) 105 (8.4) 
Spondylolisthesis 105 (6.7) 82 (6.5) 
Lumbar degenerative kyphosis 69 (4.4) 57 (4.6) 
Fracture 210 (13.3) 174 (13.9) 
Traumatic fracture 71 (4.5) 58 (4.6) 
Osteoporotic fracture 139 (8.8) 116 (9.3) 
Complex regional pain syndrome 22 (1.4) 17 (1.4) 
Infection 18 (1.1) 13 (1.0) 
Failed back surgery syndrome 128 (8.1) 109 (8.7) 
Other deformity 22 (1.4) 22 (1.8)
Others 137 (8.7) 95 (7.6)
Total 1,576 (100.0) 1,252 (100.0) 
Values are presented as number (%). 
FAS: Full data analysis set. matrix treatment within one month, they had a history of
drug abuse, they were unable to use a transdermal system
due to skin disease, they had a history of CO2 retention,
hypersensitivity to opioid analgesics or they had a serious
mental disease. Patients could also be excluded at the inves-
tigator’s discretion. 
2. Medication
TDF was administered every 72 hours, and it was gener-
ally started at a dose of 12 μ g/hr. The dose of TDF was
adjusted by the investigator depending upon the level of
pain relief. Opioids other than TDF could not be taken dur-
ing the study, but as-needed analgesics (acetaminophen,
NSAIDs), anxiolytics, antidepressants, anti-arrhythmic
drugs, corticosteroids, anticonvulsants and preventative
anti-emetics were permitted. 
3. Assessments
In addition to the scheduled visits, all the patients were
seen on demand. If emergency room visits or hospital
admission were required, then the patient was removed
from the study and he/she was treated routinely.
The patients were evaluated at baseline (day 1, Visit 1),
on day 29 (± 7, Visit 2) and day 57 (± 7, Visit 3). The pri-
mary efficacy variable was pain control, which was evaluat-
ed on an 11-point numeric rating scale (0 = no pain, 10 =
worst possible pain) during the 3 days preceding the visit.
Post-treatment pain intensity scales were used to determine
the percentage of the pain intensity difference (% PID). 
% PID = [NRS (at baseline) - NRS (at final evaluation)]
× 100 (%)/NRS (at baseline) 
The secondary efficacy assessments included the K-ODI
for assessing 10 domain scales: sleep disturbance (11-point
numeric rating scale; 0 = no disturbance, 10 = worst possi-
ble disturbance) during the preceding 3 days; daily living
and social activities (5-point verbal rating scale; 1 = very
good/no impairment, 5 = very poor/severe) during the pre-
ceding 3 days; the investigator and patient’s global assess-
ment (5-point rating scale; 1 = very poor, 5 = very good);
the patient’s preference and the clinical global impression
(improvement: very much improved to very much worse). 
Safety was evaluated by monitoring the patient’s clinical
condition and the spontaneously reported adverse events
(the occurrence, nature, intensity and relationship to the
study drug). 
4. Statistical analysis 
All the patients who received study medication and their
data was recorded at baseline and at least once thereafter
were included in the intention-to-treat population. All the
pain severity and interference analyses were carried out
using the full analysis set (The full analysis set is the group
excluding the patients who violated major inclusion/exclu-
sion criteria, who were not administered the study drug or
whose efficacy data did not exist after the study drug
administration). 
The sample size was calculated using the hypothesis that
58% of the patients would record a decrease of more than
50% in pain intensity [12] after treatment with TDF. 
The drug efficacy was evaluated in 1,252 patients (full
data analysis set [FAS]), which included 1,037 patients who
completed the last assessment in accordance with the study
plan (the per-protocol population) and 215 patients who
were excluded after the second assessment. Safety was
assessed in the total population.
The data were analyzed using SAS ver. 9.1 (SAS Institute
Inc., Cary, NC, USA). The Friedman test was used to ana-
lyze the change from baseline to the endpoint and the influ-
ence of the baseline values. The Wilcoxon signed rank test
was used to compare the intra-group results and the results
at each time point or at the endpoint with the baseline, when
applicable. The correlation between the major efficacy eval-
uation parameters and changes in the K-ODI was evaluated
using the Spearman Rho analysis. Statistical tests were
interpreted at the 5% significance level. Significant differ-
ences between baseline, week 4 and week 8 were assessed
using the paired t-test. 
Results 
1. Patients
A total of 1,576 patients (970 men and 606 women) with
an average age (standard deviation) of 62.8 (± 12.9) years
were enrolled and they received the study treatment, and
1,037 of these patients completed the study and were
included in the per protocol population (Fig. 1). The reasons
for discontinuation among the 539 patients (34.2%) who
withdrew from the trial during the treatment phase were lost
to follow-up (225), adverse events (106), patient’ s decision
(109), pain improvement (58) and other reasons (41). 
The baseline demographics and diagnoses are presented
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was degenerative spine disease including spinal stenosis.
Eighty five point three percent of the patients had received
previous treatment (93.9% medication, 17.3% surgery,
11.2% physical treatment, 9.3% other treatments). 
2. Study medication 
The mean starting dose of TDF was 13.1 μ g/hr (± 3.7, n
= 1,252). The average mean daily doses at weeks 4 and 8
were 15.5 μ g/hr (± 6.4, n = 1,252) and 16.0 μ g/hr (± 7.3,
n = 1,037), respectively. 
3. Concomitant medications 
The concomitant medications used before and during the
study are listed in Table 3. The most commonly used anal-
gesics were Ultracet
™ (Janssen Korea) (33.5%), gabapentin
(13.3%), and aceclofenac (8.8%). A total of 1,405 patients
received analgesic treatment before the study, 1,187 patients
received continuous analgesic medication and 1,367 patients
received concomitant medication during the study. There
was no statistical difference between the doses of combina-
tion analgesics taken during the study. A total of 1,252 non-
analgesic preparations were prescribed during the study,
including anti-emetics (domperidone, 160; metoclopramide,
7), laxatives (magnesium hydroxide, 6; magnesium oxide, 3)
and anti-dizziness agents (dimenhydrinate, 2). 
(1) Pain intensity 
The pain intensity significantly decreased from 8.1 points
at Visit 1 (Table 4) by 2.7 ± 1.92 points (33.5%) to 5.4 at
Visit 2 (p < 0.0001) and by 3.7 ± 2.18 points (45.3%) at
Visit 3 (p < 0.0001, Friedman test) (Fig. 2). The pain inten-
sity decreased by an average of 45.3% among all the
patients; for the patients recording a reduction of over 50%,
the average reduction was 66.1% (95% confidence interval
[CI], 65.2 to 67.1). The pain intensity among the 1,252
patients in the FAS group showed an average reduction of
44.9%; the patients with a reduction over 50% recorded an
average reduction of 66.0% (95% CI, 65.1 to 67.1). Overall,
70.9% (95% CI, 68.4 to 73.4) and 49.8% (95% CI, 47.1 to
52.6) of the patients recorded reductions in pain intensity
greater than 30% and 50%, respectively. 
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Table 3. Previous and concomitant medication (analgesics) (n = 1,252) 
Previous medication Concomitant medication 
Analgesic types No. of patients with  Rate No. of patients with continuous  Rate No. of patients with drawn from  Rate
drug administered (%) administration (%) administration (%)
Non-opioid 1,154 92.2 955 (143) 76.3 199 15.9
Weak-opioid 45 03.6 34 (5)00 2.7 011 00.9
Strong-opioid 11 00.9 7 (3) 00.6 004 00.3
PRN analgesic 9 00.7 7 (1) 00.6 002 00.2
Adjuvant analgesic 186 14.9 173 (41)0 13.8 013 00.1
Total 1,405 112 1,176 (191)0 93.9 229 18.3
Analgesic newly administered during the study period is presented in parentheses. 
PRN: Pro re nata.
Patient disposition
Fig. 1. Disposition of the study subjects. Pts: Patients, FL: Fol-
low-up loss, AE: Adverse event, PS: Patient’ s selection, PC:
Pain controlled.
4 wk
4 wk
Enrolled Pts.: 1,576
Drop-out: 324
-FL: 151 (46.6%) 
-AE: 81 (25.0%)
-PS: 45 (13.9%)
-PC: 19 (5.9%)
-etc: 28 (8.6%)
Visit 2: 1,252
Completion: 1,037
Drop-out: 215
-FL: 74 (34.4%)
-PS: 64 (29.8%)
-PC: 39 (18.1%)
-AE: 25 (11.6%)
-etc: 13 (6.0%)(2) Sleep disturbance 
Sleep disturbance significantly decreased from 6.5 points
at Visit 1 (Table 4) to 4.0 points at Visit 2 and to 3.1 points
at Visit 3 (p < 0.001, Friedman test) (Fig. 3). 
(3) Disturbance in daily living activities
Disturbance in daily living activities significantly
decreased from 4.0 points at Visit 1 (Table 4) to 2.9 points
at Visit 2 and to 2.5 points at Visit 3 (p < 0.001, Friedman
test) (Fig. 4). 
(4) Disturbance in social activities
Disturbance in social activities significantly decreased
from 4.0 points at Visit 1 (Table 4) to 2.9 points at Visit 2
and to 2.5 points at Visit 3 (p < 0.001, Friedman test) (Fig. 5).
(5) K-ODI  and  Korean  version  of  the  Neck  Disability
Index (K-NDI) 
For the 1,216 patients who were analyzed, the K-ODI sig-
nificantly decreased from 61.9% at Visit 1 to 45.8% at Visit 2
and to 38.2% at Visit 3 (p < 0.001, Friedman test) (Table 5). 
Correlation analysis between the major efficacy evalua-
tion parameters and the changes in the K-ODI demonstrated
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Table 4. Baseline evaluations (n = 1,252) 
Parameter Mean [max, min] STD 
Pain intensity (NRS 0-10) 8.1 [7, 10] 1.7
Sleep disturbance due to  6.5 [0, 10] 2.7 
pain (NRS 0-10)  
Pain interference on activity 4.0 [1, 5] 0.8 
of daily living (5 point scale: 1-5) 
Pain interference on activity of 4.0 [1, 5] 0.9 
social life (5 point scale: 1-5) 
Korean version of ODI score  61.9 18.20 
STD: Standard deviation, NRS: Numerical rating scale, ODI:
Oswestry Disability Index.
Fig. 2. Pain intensity during 8 wk of treatment with transder-
mal fentanyl (full data analysis set). 
Fig. 3. Sleep disturbance during 8 wk of treatment with trans-
dermal fentanyl (full data analysis set). 
Fig. 4. The effect of 8 wk treatment with transdermal fentanyl
upon daily living activities (full data analysis set). 
Fig. 5. The effect of 8 wk treatment with transdermal fentanyl
upon social activities (full data analysis set).a linear relationship for all the parameters, including the
rate of change of pain intensity (r = 0.66), the rate of change
of sleep disturbance (r = 0.56), the rate of change of distur-
bances in daily living activities (r = 0.66), and the rate of
change of disturbances in social activities (r = 0.63; Spear-
man correlation test, all p < 0.001). 
The K-NDI, which was analyzed for 31 patients, signifi-
cantly decreased from 58.3% at Visit 1 to 46.3% at Visit 2
and to 38.6% at Visit 3 (p < 0.001, Friedman test). 
(6) Safety analysis 
Of the 1,576 enrolled patients, 197 (12.5%) patients
reported adverse events and 12 (0.76%) patients reported
severe adverse events. Out of the 539 (25.8%) patients who
withdrew from the study, an adverse event was the major
cause of drop-out for 139 patients. The most common
symptoms included dizziness, nausea, vomiting, itching and
headache; the incidence of vomiting was 3.4% (20.4% of
the severe adverse events), but all other symptoms occurred
in fewer than 4% of the patients (Table 6). Withdrawal syn-
drome was not reported and no deaths occurred during the
study. There were no clinically significant changes of the
vital signs during the study. 
(7) Global assessments 
According to the patients’ overall assessment, 70.6% and
76.3% of patients rated the treatment as effective during
Visits 2 and 3, respectively. The increase from Visits 2 to 3
was statistically significant (p < 0.001, McNemar test). 
The investigator’s overall assessment rated the treatment
as effective in 73.9% and 78.4% of patients at Visits 2 and
3, respectively. The increase from Visits 2 to 3 was statisti-
cally significant (p < 0.001, McNemar test). 
The investigators’ clinical global impression of
‘improved/greatly improved’ rose from 39.4% during Visit
2 to 54.7% during Visit 3. The increase in the response rate
from Visit 2 to Visit 3 was statistically significant (p <
0.001, McNemar test) (Fig. 6). 
With respect to patient preference, 89.5% of the 1,146
respondents preferred TDF over their previously used anal-
gesics. The reasons cited were constant pain relief (71.3%),
sleep improvement (11.9%), greater convenience as a result
of fewer drug administrations (12.7%), reduction of opioid
administration (2.7%) and others (1.5%). Notably, 876
(84.5%) patients continued the use of the test drug even
after the completion of the study. 
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Table 5. Overall evaluation of K-ODI (n = 1,216) 
Section
Primary evaluation Secondary evaluation Tertiary evaluation Friedman test
No. Ave (STD) No. Ave (STD) No. Ave (STD) p-value
Pain intensity 1,216 3.79 (0.77) 1,203 2.67 (0.95)  1,197 2.20 (1.03) < 0.001
Personal care 1,216 2.80 (1.24) 1,203 1.94 (1.10) 1,197 1.57 (1.10) < 0.001
Lifting 1,214 3.64 (1.08) 1,203 2.96 (1.16) 1,196 2.55 (1.27) < 0.001
Walking 1,214 2.68 (1.34) 1,205 2.02 (1.21) 1,195 1.70 (1.21) < 0.001
Sitting 1,215 2.82 (1.24) 1,206 2.06 (1.07) 1,194 1.68 (1.06) < 0.001
Standing 1,214 3.17 (1.19) 1,201 2.36 (1.16) 1,195 1.98 (1.20) < 0.001
Sleeping 1,215 2.67 (1.40) 1,204 1.75 (1.16) 1,197 1.38 (1.10) < 0.001
Sexual life 1,479 3.22 (1.50) 1,417 2.62 (1.53) 1,403 2.21 (1.56) < 0.001
Social life 1,212 3.07 (1.19) 1,202 2.38 (1.16) 1,195 2.02 (1.21) < 0.001
Traveling 1,212 3.15 (1.32) 1,201 2.36 (1.23) 1,193 1.98 (1.25) < 0.001
K-ODI: Korean version of Oswestry Disability Index, Ave (STD): Average (standard deviation).
Table 6. Summary of main adverse events (n = 1,576) 
Adverse events No. (%)
Causality Severity 
+ (%) - (%) Mild (%) Moderate (%) Severe (%)
Dizziness 59 (3.7) 58 (98.3) 1 (1.7) 24 (40.7) 29 (49.2) 6 (10.1)
Nausea 58 (3.7) 58 (100.0) 0 (0.0) 26 (44.8) 28 (48.3) 4 (6.9)
Vomiting 54 (3.4) 54 (100.0) 0 (0.0) 16 (29.6) 27 (50.0) 12 (20.4)
Itching 16 (1.0) 16 (100.0) 0 (0.0) 7 (43.8) 7 (43.8) 2 (12.4)
Headache 9 (0.6) 9 (100.0) 0 (0.0) 3 (33.3) 5 (55.6) 1 (11.1)Discussion 
Although this study was only designed to evaluate the
utility of TDF under routine conditions and to investigate
different practical issues, it was valuable because it
prospectively assessed the patients’ reaction to TDF treat-
ment in a large scale analysis and the patients were being
treated currently for spine related chronic pain. 
A statistically significant decrease in pain intensity was
demonstrated during the study, and especially in terms of
the degree of clinically significant pain reduction; the per-
centage of patients with over 30% and 50% reductions in
pain intensity after treatment was 70.9% and 49.8%, respec-
tively. Furthermore, although this study was not placebo-
controlled, over three quarters of the patients and investiga-
tors valued the drug to be ‘greatly effective or effective;’
more than half the patients reported that their pain was
‘greatly improved or improved’ compared to the pre-TDF
treatment. The majority of patients preferred TDF over the
previously used analgesics, and this was predominantly
because of the stable pain relief during drug administration.
Our results indicated that TDF provided significant pain
relief in the majority of patients and that the degree of pain
relief was significantly better compared to that of the previ-
ous medication. Yet there was not a significant difference in
the frequency or dosage of concomitant medication between
before and after TDF treatment; indeed, only 3 patients
started using strong opioids.  Needless to say, it would be
preferable to exclude such concomitant medication when
assessing the utility of TDF, but it is much more appropri-
ate, from a pharmacological and ethical perspective, to
allow the use of rescue medication for the treatment of
break-through pain in patients who are taking long acting
opioids such as fentanyl. The use of concomitant medica-
tion in this study did not decrease significantly because the
dose of TDF administered at Visit 3 was only 16 μ g/hr,
which is relatively low compared to the doses used in other
studies. Nevertheless, the significant reduction in pain
intensity irrespective of the low TDF dose in the patients
with a NRS score of at least 7 and who had suffered from
chronic pain for over 3 months despite previous treatment
indicates the effectiveness of TDF. 
In addition to the improvements in pain intensity, all the
other parameters, including sleep disturbance due to pain
and the degree of disturbance in daily living and social
activities, significantly improved after week 8 as compared
to pre-treatment. All 10 parameters measured with the K-
ODI showed significant improvement compared with the
pre-treatment values. The total K-ODI score was also sig-
nificantly improved after treatment as compared with the
score measured before the treatment started. This supports
the notion that pain severely limits movement and that
effective pain treatment could help patients to improve their
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Fig. 6. Clinical global impression (per-protocol population). daily living and social activities [13]. There was a positive
correlation between the K-ODI scores and the rate of
change of the pain intensity, the degree of sleep disturbance
and the degree of disturbance in daily living and social
activities following pain treatment, indicating that TDF
improves not only pain treatment, but also the patient’ s
function. This finding, which is one of the important goals
for the treatment of patients with chronic pain, is therefore
clinically significant. 
Of the 1,576 patients who received at least one dose of
the study drug, the percentage of patients who experienced
adverse events was 12.5%. In addition, the percentage of
patients experiencing adverse events among the 1,037
patients who completed the 8 week study was only 5.6%.
This relatively low incidence and the nature of these
adverse events recorded in this study were consistent with
the other TDF trials and with strong opioids in general
[8,14]. However, the relatively low frequency and intensity
of adverse events may also have resulted from the low start-
ing dose of TDF, which was chosen based on a previously
reported observation that 12 μ g/hr compared to 25 μ g/hr
does not lead to a big difference in pain relief, but the fre-
quency of adverse events is much lower [15]. 
Tolerability is a very important issue with opioid treat-
ment. Indeed, there have been cases where opioids with
excellent analgesic properties failed to be used therapeuti-
cally due to the adverse events at the onset of treatment, and
notably nausea, vomiting and dizziness. In this study, the
withdrawal rate due to adverse events was highest during
the early trial period and it was especially high at the initia-
tion of the treatment. Concomitant treatment with dom-
peridone (160 cases) and metoclopramide (7 cases) was pre-
scribed for nausea and vomiting in this study. However,
such adverse events tend to be self-limiting and transient
and they can often be managed with prophylactic medica-
tions. 
The incidence of severe adverse events at the initiation of
therapy could hinder the use of a drug and so it is very
important to use a low dose at the early stage, as was done
in this study, in order to increase patient tolerability. Consti-
pation occurred in only 9 out of 1,576 patients. These
results are similar to those of the previous trials with TDF,
and they support the benefits of TDF over oral treatments
[13,16]. Indeed, TDF caused less constipation in patients
with chronic non-cancer pain and cancer pain compared to
that of sustained-release oral morphine [16,17]. According-
ly, the 12 μ g/hr TDF patch used in this study was shown to
be very effective [18] because it allows gradual dose titra-
tion based on the efficacy while lowering the incidence of
adverse events [11]. 
The present study was an open-label trial of a relatively
short duration, and it has several potential limitations, includ-
ing the possibility of bias. Thus, the results should be inter-
preted with caution. Being an observational study, this study
did not set the degree of pain control as the guideline for
treatment. So, the treatment dosage of TDF was not increased
systematically; this led to the NRS remaining at 4.1 despite 8
weeks of treatment and 57.4% of patients still complained of
moderate to severe pain. Such findings could be the result of
using a relatively low TDF dose of 16.8 μ g/hr during the 8
week treatment period, and this may have led to a failure to
administer the required dose of drug, as based on pain inten-
sity. There were also limitations with respect to assessing
the efficacy of TDF for the treatment of pain due to the
allowed administration of concomitant analgesics. Howev-
er, based on the observed improvements in the pain intensi-
ty through the introduction of TDF in the patients who had
not benefited from previous analgesics for the treatment of
chronic pain for 3 or more months, and there was no
increase in the type or dose of TDF, it would not be unrea-
sonable to conclude that TDF is effective for the treatment
of pain. 
Conclusions
In this study, the use of TDF led to additional pain control
and improved functioning, including sleep and the daily and
social activities. Thus, it can be concluded that TDF is
effective for the treatment of spinal disorder-related chron-
ic, severe pain. However, physicians should pay attention to
cautiously prescribe TDF because opioids are associated
with potentially serious harm, including opioid-related
adverse effects and outcomes related to the abuse potential
of opioids. 
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